Information Provided By: 
Fly News Breaks for January 22, 2018
CBAY, PTLA, NBIX
Jan 22, 2018 | 07:37 EDT
Oppenheimer analyst Jay Olson notes that driven by tax reform and cash repatriation, Biotech investors expect increased M&A activity. The analyst believes tax reform with cash repatriation will increase firepower of potential buyers, and points out that managements stated interest in targets with strategic fit. In his coverage universe, Olson believes Neurocrine (NBIX), Portola Pharmaceuticals (PTLA) and CymaBay (CBAY) shares could benefit from increased M&A based on their therapeutic areas and strategic fit.
News For NBIX;PTLA;CBAY From the Last 2 Days
NBIX
Apr 23, 2024 | 10:29 EDT
CBAY
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
